Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up

• Auteurs principaux: Antonio Lacquaniti (Auteur), Patrizio Pasqualetti (Auteur), Teresa Casuscelli di Tocco (Auteur), Susanna Campo (Auteur), Stefania Rovito (Auteur), Maurizio Bucca (Auteur), Antonino Ragusa (Auteur), Paolo Monardo (Auteur)
• Format: Livre
• Publié: The Korean Society of Nephrology, 2020-09-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Background : : Ferric carboxymaltose (FCM) is a parenteral, dextran-free iron formulation designed to overcome the limitations of existing iron preparations. The main aim of this study was to retrospectively examine results obtained from a long period of FCM therapy in hemodialysis patients who have...